Journal of Clinical Oncology, Vol 19, Issue 5
(March), 2001: 1279-1287
© 2001 American Society for Clinical Oncology
Glutathione S-Transferase Polymorphisms and Outcome of Chemotherapy in Childhood Acute Myeloid Leukemia
By Stella M. Davies,
Leslie L. Robison,
Jonathan D. Buckley,
Tom Tjoa,
William G. Woods,
Gretchen A. Radloff,
Julie A. Ross,
John P. Perentesis
From the Department of Pediatrics, University of Minnesota, Minneapolis, MN; South Carolina Cancer Center, Columbia, SC; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles; and the Childrens Cancer Group, Arcadia, CA.
Address reprint requests to S.M. Davies, MB, BS, PhD, Childrens Cancer Group, PO Box 60012, Arcadia, CA 91066-6012; email: davie008{at}tc.umn.edu
PURPOSE: Glutathione S-transferase theta (GSTT1) and mu (GSTM1) genes are polymorphic, the genes being absent in approximately 15% and 50% of the population, respectively. Because glutathione S-transferases may be involved in the metabolism of chemotherapy drugs, we hypothesized that presence or absence of the genes may influence the outcome of treatment for childhood acute myeloid leukemia (AML).
PATIENTS AND METHODS: We genotyped GSTT1 and GSTM1 in 306 children with AML receiving chemotherapy on Childrens Cancer Group therapeutic studies. Outcomes were compared in those with and without GSTT1 and GSTM1 genes.
RESULTS: Patients with the GSTT1-negative genotype had reduced survival compared with those with at least one GSTT1 allele (GSTT1 positive) (52% v 40% at 5 years; log-rank P = .05). A multivariate model of survival adjusted for age group, sex, WBC count, chloroma, CNS involvement, and French-American-British group confirmed the increased risk of death in the GSTT1-null cases (relative risk,AQ 1.6; P = .02). The frequency of death in remission was increased in GSTT1-negative cases compared with GSTT1-positive cases (24% v 12%, log-rank P = .05). The frequency of relapse from end of induction was similar in GSTT1-negative and GSTT1-positive cases (38% v 35%, log-rank P = .5).
CONCLUSION: Children who lacked GSTT1 had greater toxicity and reduced survival after chemotherapy for AML compared with children with at least one GSTT1 allele. If confirmed in further studies, GSTT1 genotype might be useful in selecting appropriate chemotherapy regimens for children with AML.
This article has been cited by other articles:

|
 |

|
 |
 
B. D. Lawenda, K. M. Kelly, E. J. Ladas, S. M. Sagar, A. Vickers, and J. B. Blumberg
Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?
J Natl Cancer Inst,
June 4, 2008;
100(11):
773 - 783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J.L. Kaspers and C. M. Zwaan
Pediatric acute myeloid leukemia: towards high-quality cure of all patients
Haematologica,
November 1, 2007;
92(11):
1519 - 1532.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Howell, K. C. Ward, H. D. Austin, J. L. Young, and W. G. Woods
Access to Pediatric Cancer Care by Age, Race, and Diagnosis, and Outcomes of Cancer Treatment in Pediatric and Adolescent Patients in the State of Georgia
J. Clin. Oncol.,
October 10, 2007;
25(29):
4610 - 4615.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso
Therapy-related leukemia and myelodysplasia: susceptibility and incidence
Haematologica,
October 1, 2007;
92(10):
1389 - 1398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Monzo, S. Brunet, A. Urbano-Ispizua, A. Navarro, G. Perea, J. Esteve, R. Artells, M. Granell, J. Berlanga, J. M. Ribera, et al.
Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
Blood,
June 15, 2006;
107(12):
4871 - 4879.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-M. Lee, M.-T. Wu, Y.-C. Lee, S.-Y. Yang, J.-S. Chen, H.-H. Hsu, P.-M. Huang, S.-W. Kuo, C.-J. Lee, and C.-J. Chen
Association of GSTP1 Polymorphism and Survival for Esophageal Cancer
Clin. Cancer Res.,
July 1, 2005;
11(13):
4749 - 4753.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Allan, A. G. Smith, K. Wheatley, R. K. Hills, L. B. Travis, D. A. Hill, D. M. Swirsky, G. J. Morgan, and C. P. Wild
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy
Blood,
December 15, 2004;
104(13):
3872 - 3877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Okcu, M. Selvan, L.-E Wang, L. Stout, R. Erana, G. Airewele, P. Adatto, K. Hess, F. Ali-Osman, M. Groves, et al.
Glutathione S-Transferase Polymorphisms and Survival in Primary Malignant Glioma
Clin. Cancer Res.,
April 15, 2004;
10(8):
2618 - 2625.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. L. Carroll
Race and Outcome in Childhood Acute Lymphoblastic Leukemia
JAMA,
October 15, 2003;
290(15):
2061 - 2063.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sweeney, V. Nazar-Stewart, P. L. Stapleton, D. L. Eaton, and T. L. Vaughan
Glutathione S-transferase M1, T1, and P1 Polymorphisms and Survival among Lung Cancer Patients
Cancer Epidemiol. Biomarkers Prev.,
June 1, 2003;
12(6):
527 - 533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W E Evans
Pharmacogenomics: marshalling the human genome to individualise drug therapy
Gut,
May 1, 2003;
52(90002):
ii10 - 18.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. S. Baker, J. R. Anderson, T. E. Lobe, M. D. Wharam, S. J. Qualman, R. B. Raney, F. B. Ruymann, R. B. Womer, W. H. Meyer, M. P. Link, et al.
Children From Ethnic Minorities Have Benefited Equally as Other Children From Contemporary Therapy for Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Study Group
J. Clin. Oncol.,
November 15, 2002;
20(22):
4428 - 4433.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. T. Voso, F. D'Alo', R. Putzulu, L. Mele, A. Scardocci, P. Chiusolo, R. Latagliata, F. Lo-Coco, S. Rutella, L. Pagano, et al.
Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia
Blood,
September 26, 2002;
100(8):
2703 - 2707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Stoehlmacher, D. J. Park, W. Zhang, S. Groshen, D. D. Tsao-Wei, M. C. Yu, and H.-J. Lenz
Association Between Glutathione S-Transferase P1, T1, and M1 Genetic Polymorphism and Survival of Patients With Metastatic Colorectal Cancer
J Natl Cancer Inst,
June 19, 2002;
94(12):
936 - 942.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Pinkel, W. G. Woods, B. J. Lange, F. O. Smith, and T. A. Alonzo
Treatment of children with acute myeloid leukemia
Blood,
June 1, 2001;
97(11):
3673 - 3675.
[Full Text]
[PDF]
|
 |
|
|